LifeStance Health Group (NASDAQ:LFST) Posts Earnings Results, Beats Expectations By $0.03 EPS

LifeStance Health Group (NASDAQ:LFST) posted its quarterly earnings data on Wednesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03, Briefing.com reports. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The business had revenue of $403.48 million during the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group’s revenue for the quarter was up 21.2% compared to the same quarter last year.

LifeStance Health Group Price Performance

NASDAQ:LFST traded up $1.49 during trading hours on Thursday, reaching $8.85. 13,778,238 shares of the company’s stock were exchanged, compared to its average volume of 4,296,210. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $3.43 billion, a P/E ratio of 442.72 and a beta of 1.20. LifeStance Health Group has a 12 month low of $3.74 and a 12 month high of $8.89. The business’s 50-day simple moving average is $6.80 and its two-hundred day simple moving average is $6.68.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q1 beat — LifeStance reported Q1 revenue of $403.5M (up ~21% YoY) and EPS of $0.04, both above consensus, which is driving the bullish reaction. Read More.
• Positive Sentiment: Raised revenue guidance — Management updated Q2 and FY2026 revenue ranges above Street revenue expectations (Q2: $405M–$425M; FY: ~$1.6B–$1.7B), supporting the stock rally by signaling continued top-line growth. Read More.
• Positive Sentiment: Board authorized a concurrent repurchase of up to 6M shares — the buyback can partially offset selling pressure from the secondary and is being highlighted as shareholder-friendly. Read More.
• Neutral Sentiment: Earnings call transcript and slide deck are available for detail — analysts and investors are parsing margins, clinician growth, and reimbursement commentary from the call. Read More.
• Negative Sentiment: Large secondary offering by existing stockholders: 35M shares will be sold by selling stockholders (LifeStance receives no proceeds). That raises near-term supply and volatility risk; heavy insider/related-party selling is noted in filings. Investors must weigh the selling pressure against the 6M-share repurchase. Read More. · Read More.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. UBS Group upped their target price on LifeStance Health Group from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Barclays lifted their price target on LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, March 6th. KeyCorp boosted their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. Finally, BTIG Research lifted their target price on LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, LifeStance Health Group currently has an average rating of “Buy” and a consensus price target of $9.83.

Insider Buying and Selling at LifeStance Health Group

In related news, Director Robert Bessler sold 62,147 shares of LifeStance Health Group stock in a transaction on Friday, April 24th. The stock was sold at an average price of $7.05, for a total value of $438,136.35. Following the transaction, the director directly owned 1,274,448 shares in the company, valued at $8,984,858.40. The trade was a 4.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Darren M. Black sold 4,314,939 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $7.01, for a total value of $30,247,722.39. Following the sale, the director directly owned 29,209,776 shares in the company, valued at $204,760,529.76. This trade represents a 12.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,389,939 shares of company stock worth $30,775,881 in the last ninety days. 3.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey lifted its stake in LifeStance Health Group by 17.4% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 43,523 shares of the company’s stock valued at $306,000 after buying an additional 6,442 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in shares of LifeStance Health Group in the fourth quarter worth approximately $273,000. Fox Run Management L.L.C. purchased a new position in shares of LifeStance Health Group in the fourth quarter worth approximately $210,000. Brevan Howard Capital Management LP acquired a new stake in shares of LifeStance Health Group during the second quarter valued at approximately $165,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of LifeStance Health Group during the third quarter valued at approximately $142,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group announced that its Board of Directors has authorized a share buyback program on Wednesday, February 25th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to purchase up to 3.6% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.